Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Harnessing the Potential of Multiomics Studies for Precision Medicine in Infectious Disease. Open forum infectious diseases Ward, R. A., Aghaeepour, N., Bhattacharyya, R. P., Clish, C. B., Gaudilliere, B., Hacohen, N., Mansour, M. K., Mudd, P. A., Pasupneti, S., Presti, R. M., Rhee, E. P., Sen, P., Spec, A., Tam, J. M., Villani, A., Woolley, A. E., Hsu, J. L., Vyas, J. M. 2021; 8 (11): ofab483

Abstract

The field of infectious diseases currently takes a reactive approach and treats infections as they present in patients. Although certain populations are known to be at greater risk of developing infection (eg, immunocompromised), we lack a systems approach to define the true risk of future infection for a patient. Guided by impressive gains in "omics" technologies, future strategies to infectious diseases should take a precision approach to infection through identification of patients at intermediate and high-risk of infection and deploy targeted preventative measures (ie, prophylaxis). The advances of high-throughput immune profiling by multiomics approaches (ie, transcriptomics, epigenomics, metabolomics, proteomics) hold the promise to identify patients at increased risk of infection and enable risk-stratifying approaches to be applied in the clinic. Integration of patient-specific data using machine learning improves the effectiveness of prediction, providing the necessary technologies needed to propel the field of infectious diseases medicine into the era of personalized medicine.

View details for DOI 10.1093/ofid/ofab483

View details for PubMedID 34805429